Business Standard

Thursday, December 19, 2024 | 08:46 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

With focus on non-US geographies, Amneal Pharma eyes India market

The company is actively recruiting its field force, and aims to have 600-700 medical representatives by the end of 2023

Pharma Sector, Pharma Companies
Premium

Sohini Das Mumbai
New Jersey headquartered $2.1 bn Amneal Pharmaceuticals is now betting on specialised and differentiated products to build its presence in the Indian pharmaceutical market (IPM), as it eyes $ 1 bn revenues by 2030 from non-US geographies.

Founded by two Indian-origin brothers Chirag and Chintu Patel in 2002, Amneal is the fifth largest generics player in the US market by prescriptions, and has begun commercial operations in India from October last year. It has had presence through manufacturing and R&D footprint in India since 2008, and currently has five formulations and two active pharmaceutical ingredients (API) plants here.

Currently, Amneal

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in